Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

Enrica Borsi, Giulia Perrone, Carolina Terragna, Marina Martello, Angela F. Dico, Giancarlo Solaini, Alessandra Baracca, Gianluca Sgarbi, Gianandrea Pasquinelli, Sabrina Valente, Elena Zamagni, Paola Tacchetti, Giovanni Martinelli, Michele Cavo

Research output: Contribution to journalArticle

Abstract

The increasing importance of hypoxia-inducible factor-1a (HIF-1a) in tumorigenesis raises the possibility that agents which specifically inhibit this transcription factor, would provide significant therapeutic benefit. The constitutive expression of HIF-1a in about 35% of Multiple Myeloma (MM) patients suggests HIF- 1a suppression might be part of a therapeutic strategy. Accordingly, we explored the effect of EZN-2968, a small 3rd generation antisense oligonucleotide against HIF-1a, in a panel of MM cell lines and primary patients samples. Here, we demonstrated that EZN-2968 is highly specific for HIF-1a mRNA and that exposure of MM cells to EZN-2968 resulted in an efficient and homogeneous loading of the cells showing a long lasting low HIF-1a protein level. In MM cells, HIF-1a suppression induced a permanent cell cycle arrest by prolonging S-phase through cyclin A modulation and in addition it induced a mild apoptotic cell death. Moreover, HIF-1a suppression caused a metabolic shift that leaded to increased production of ATP by oxidative phosphorylation (i.e. Warburg effect reversion), that was confirmed by the observed mitochondrial membrane potential decrease. These results show that HIF-1a is an important player in MM homeostasis and that its inhibition by small antisense oligonucleotides provides a rationale for novel therapeutic strategy to improving MM treatment.

Original languageEnglish
Pages (from-to)1779-1792
Number of pages14
JournalOncotarget
Volume5
Issue number7
Publication statusPublished - 2014

Fingerprint

Hypoxia-Inducible Factor 1
Multiple Myeloma
Antisense Oligonucleotides
Therapeutics
Cell Hypoxia
Cyclin A
Mitochondrial Membrane Potential
Oxidative Phosphorylation
Cell Cycle Checkpoints
Hypoxia
S Phase
Carcinogenesis
Homeostasis
Cell Death
Transcription Factors
Adenosine Triphosphate
Cell Line
Messenger RNA

Keywords

  • Cell cycle
  • HIF-1a
  • Mitochondria
  • Multiple myeloma
  • Warburg effect

ASJC Scopus subject areas

  • Oncology

Cite this

Borsi, E., Perrone, G., Terragna, C., Martello, M., Dico, A. F., Solaini, G., ... Cavo, M. (2014). Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget, 5(7), 1779-1792.

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. / Borsi, Enrica; Perrone, Giulia; Terragna, Carolina; Martello, Marina; Dico, Angela F.; Solaini, Giancarlo; Baracca, Alessandra; Sgarbi, Gianluca; Pasquinelli, Gianandrea; Valente, Sabrina; Zamagni, Elena; Tacchetti, Paola; Martinelli, Giovanni; Cavo, Michele.

In: Oncotarget, Vol. 5, No. 7, 2014, p. 1779-1792.

Research output: Contribution to journalArticle

Borsi, E, Perrone, G, Terragna, C, Martello, M, Dico, AF, Solaini, G, Baracca, A, Sgarbi, G, Pasquinelli, G, Valente, S, Zamagni, E, Tacchetti, P, Martinelli, G & Cavo, M 2014, 'Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma', Oncotarget, vol. 5, no. 7, pp. 1779-1792.
Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G et al. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget. 2014;5(7):1779-1792.
Borsi, Enrica ; Perrone, Giulia ; Terragna, Carolina ; Martello, Marina ; Dico, Angela F. ; Solaini, Giancarlo ; Baracca, Alessandra ; Sgarbi, Gianluca ; Pasquinelli, Gianandrea ; Valente, Sabrina ; Zamagni, Elena ; Tacchetti, Paola ; Martinelli, Giovanni ; Cavo, Michele. / Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. In: Oncotarget. 2014 ; Vol. 5, No. 7. pp. 1779-1792.
@article{0963614ebbcc4056af6a99fefea26f85,
title = "Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma",
abstract = "The increasing importance of hypoxia-inducible factor-1a (HIF-1a) in tumorigenesis raises the possibility that agents which specifically inhibit this transcription factor, would provide significant therapeutic benefit. The constitutive expression of HIF-1a in about 35{\%} of Multiple Myeloma (MM) patients suggests HIF- 1a suppression might be part of a therapeutic strategy. Accordingly, we explored the effect of EZN-2968, a small 3rd generation antisense oligonucleotide against HIF-1a, in a panel of MM cell lines and primary patients samples. Here, we demonstrated that EZN-2968 is highly specific for HIF-1a mRNA and that exposure of MM cells to EZN-2968 resulted in an efficient and homogeneous loading of the cells showing a long lasting low HIF-1a protein level. In MM cells, HIF-1a suppression induced a permanent cell cycle arrest by prolonging S-phase through cyclin A modulation and in addition it induced a mild apoptotic cell death. Moreover, HIF-1a suppression caused a metabolic shift that leaded to increased production of ATP by oxidative phosphorylation (i.e. Warburg effect reversion), that was confirmed by the observed mitochondrial membrane potential decrease. These results show that HIF-1a is an important player in MM homeostasis and that its inhibition by small antisense oligonucleotides provides a rationale for novel therapeutic strategy to improving MM treatment.",
keywords = "Cell cycle, HIF-1a, Mitochondria, Multiple myeloma, Warburg effect",
author = "Enrica Borsi and Giulia Perrone and Carolina Terragna and Marina Martello and Dico, {Angela F.} and Giancarlo Solaini and Alessandra Baracca and Gianluca Sgarbi and Gianandrea Pasquinelli and Sabrina Valente and Elena Zamagni and Paola Tacchetti and Giovanni Martinelli and Michele Cavo",
year = "2014",
language = "English",
volume = "5",
pages = "1779--1792",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "7",

}

TY - JOUR

T1 - Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

AU - Borsi, Enrica

AU - Perrone, Giulia

AU - Terragna, Carolina

AU - Martello, Marina

AU - Dico, Angela F.

AU - Solaini, Giancarlo

AU - Baracca, Alessandra

AU - Sgarbi, Gianluca

AU - Pasquinelli, Gianandrea

AU - Valente, Sabrina

AU - Zamagni, Elena

AU - Tacchetti, Paola

AU - Martinelli, Giovanni

AU - Cavo, Michele

PY - 2014

Y1 - 2014

N2 - The increasing importance of hypoxia-inducible factor-1a (HIF-1a) in tumorigenesis raises the possibility that agents which specifically inhibit this transcription factor, would provide significant therapeutic benefit. The constitutive expression of HIF-1a in about 35% of Multiple Myeloma (MM) patients suggests HIF- 1a suppression might be part of a therapeutic strategy. Accordingly, we explored the effect of EZN-2968, a small 3rd generation antisense oligonucleotide against HIF-1a, in a panel of MM cell lines and primary patients samples. Here, we demonstrated that EZN-2968 is highly specific for HIF-1a mRNA and that exposure of MM cells to EZN-2968 resulted in an efficient and homogeneous loading of the cells showing a long lasting low HIF-1a protein level. In MM cells, HIF-1a suppression induced a permanent cell cycle arrest by prolonging S-phase through cyclin A modulation and in addition it induced a mild apoptotic cell death. Moreover, HIF-1a suppression caused a metabolic shift that leaded to increased production of ATP by oxidative phosphorylation (i.e. Warburg effect reversion), that was confirmed by the observed mitochondrial membrane potential decrease. These results show that HIF-1a is an important player in MM homeostasis and that its inhibition by small antisense oligonucleotides provides a rationale for novel therapeutic strategy to improving MM treatment.

AB - The increasing importance of hypoxia-inducible factor-1a (HIF-1a) in tumorigenesis raises the possibility that agents which specifically inhibit this transcription factor, would provide significant therapeutic benefit. The constitutive expression of HIF-1a in about 35% of Multiple Myeloma (MM) patients suggests HIF- 1a suppression might be part of a therapeutic strategy. Accordingly, we explored the effect of EZN-2968, a small 3rd generation antisense oligonucleotide against HIF-1a, in a panel of MM cell lines and primary patients samples. Here, we demonstrated that EZN-2968 is highly specific for HIF-1a mRNA and that exposure of MM cells to EZN-2968 resulted in an efficient and homogeneous loading of the cells showing a long lasting low HIF-1a protein level. In MM cells, HIF-1a suppression induced a permanent cell cycle arrest by prolonging S-phase through cyclin A modulation and in addition it induced a mild apoptotic cell death. Moreover, HIF-1a suppression caused a metabolic shift that leaded to increased production of ATP by oxidative phosphorylation (i.e. Warburg effect reversion), that was confirmed by the observed mitochondrial membrane potential decrease. These results show that HIF-1a is an important player in MM homeostasis and that its inhibition by small antisense oligonucleotides provides a rationale for novel therapeutic strategy to improving MM treatment.

KW - Cell cycle

KW - HIF-1a

KW - Mitochondria

KW - Multiple myeloma

KW - Warburg effect

UR - http://www.scopus.com/inward/record.url?scp=84898928636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898928636&partnerID=8YFLogxK

M3 - Article

C2 - 24732040

AN - SCOPUS:84898928636

VL - 5

SP - 1779

EP - 1792

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -